Search results for " Skin"

showing 10 items of 1220 documents

Associations between neuropsychological performance and appetite-regulating hormones in anorexia nervosa and healthy controls: Ghrelin's putative rol…

2019

Anorexia nervosa (AN) is a severe eating disorder accompanied by alterations in endocrinological circuits and deficits in neuropsychological performance. In this study, a series of appetite-regulating hormones (ghrelin, leptin, cholecystokinin, PYY, adiponectin, and visfatin) were measured under fasting conditions in female patients with AN and female healthy controls. All of the participants also underwent a battery of neuropsychological assessment [namely the Iowa Gambling Task (IGT), the Wisconsin Card Sorting Test (WCST), and the Stroop Color and Word Test (SCWT)]. As the main finding, we found that higher ghrelin levels predict better performance in the IGT. Ghrelin may be a putative m…

0301 basic medicineAdultmedicine.medical_specialtyAnorexia Nervosamedia_common.quotation_subjectDecision MakingAppetite030209 endocrinology & metabolismNeuropsychological TestsBiochemistryModels BiologicalCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyWisconsin Card Sorting TestInternal medicineAppetite regulationmedicineHumansNeuropsychological assessmentMolecular Biologymedia_commonmedicine.diagnostic_testbusiness.industryLeptindigestive oral and skin physiologyAppetiteAnorexia nervosaIowa gambling taskNeuropsychological performanceGhrelin030104 developmental biologyEndocrinologyAnorexia nervosa (differential diagnoses)Case-Control StudiesGhrelinbusinesshormones hormone substitutes and hormone antagonistsStroop effectDecision-making
researchProduct

Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.

2015

Peer reviewed

0301 basic medicineAdultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmenteducationPain5-AMINOLEVULINIC ACIDHuman skinPhotodynamic therapyPilot ProjectsEUROPEAN GUIDELINESDermatology030105 genetics & heredityAdministration Cutaneousphotodynamic therapy (PDT)ihosyöpä03 medical and health sciencesDouble-Blind MethodMedicineHumansPhotosensitizerProdrugsSkinACTINIC KERATOSESihoPhotosensitizing Agentsbusiness.industryGeneral MedicineActinic keratosesAminolevulinic AcidDermatologyHealthy Volunteers3. Good healthOikeuslääketiede ja muut lääketieteet - Forensic science and other medical sciencesREDUCES INFLAMMATIONPhotochemotherapyErythema3121 General medicine internal medicine and other clinical medicinebusinessActa dermato-venereologica
researchProduct

Coffee silverskin extract protects against accelerated aging caused by oxidative agents

2016

Nowadays, coffee beans are almost exclusively used for the preparation of the beverage. The sustainability of coffee production can be achieved introducing new applications for the valorization of coffee by-products. Coffee silverskin is the by-product generated during roasting, and because of its powerful antioxidant capacity, coffee silverskin aqueous extract (CSE) may be used for other applications, such as antiaging cosmetics and dermaceutics. This study aims to contribute to the coffee sector’s sustainability through the application of CSE to preserve skin health. Preclinical data regarding the antiaging properties of CSE employing human keratinocytes and Caenorhabditis elegans are col…

0301 basic medicineAgingAntioxidantmedicine.medical_treatmentdermaceuticPharmaceutical ScienceCoffeamedicine.disease_causeAntioxidantsAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineDrug Discoveryoxidative stressFood sciencenutricosmeticCellular SenescenceRoastingChemistryOxidantsChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular Medicinecoffee silverskincoffee silverskin; oxidative stress; UVC radiation; chlorogenic acid; skin health; accelerated aging; nutricosmetic; dermaceuticskin healthCell SurvivalUltraviolet Rayschlorogenic acidOxidative phosphorylationArticlelcsh:QD241-441UVC radiation03 medical and health scienceslcsh:Organic chemistryChlorogenic acidCell Line Tumorparasitic diseasesmedicineaccelerated agingAnimalsHumansPhenolsPhysical and Theoretical ChemistryCaenorhabditis elegansPlant Extractsbusiness.industryOrganic ChemistryAccelerated agingBiotechnologyOxidative StressHaCaT030104 developmental biologyReactive Oxygen SpeciesbusinessBiomarkersOxidative stress
researchProduct

Raman Spectroscopic Measurements of Dermal Carotenoids in Breast Cancer Operated Patients Provide Evidence for the Positive Impact of a Dietary Regim…

2015

Dermal carotenoids are a feasible marker of the body antioxidative network and may reveal a moderate to severe imbalance of the redox status, thereby providing indication of individual oxidative stress. In this work noninvasive Resonance Raman Spectroscopy (RRS) measurements of skin carotenoids (skin carotenoid score (SCS)) were used to provide indications of individual oxidative stress, each year for five years, in 71 breast cancer (BC) patients at high risk of recurrence. Patients’ SCS has been correlated with parameters relevant to BC risk, waist circumference (WC), and body mass index (BMI), in the aim of monitoring the effect of a dietary regimen intended to positively affect BC risk f…

0301 basic medicineAgingmedicine.medical_specialtyPathologyWaistTime FactorsArticle SubjectBreast Neoplasmsmedicine.disease_causeSpectrum Analysis RamanBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicineVegetablesmedicineantioxidants skin carotenoids oxidative stress breast cancer Raman spectroscopyHumanslcsh:QH573-671Carotenoidchemistry.chemical_classification030109 nutrition & dieteticsAnthropometryintegumentary systembusiness.industrylcsh:Cytologyfood and beveragesCell BiologyGeneral MedicineAnthropometrymedicine.diseasePrognosisCarotenoidsLycopeneDietOxidative Stresschemistry030220 oncology & carcinogenesisFruitFemalebusinessDietary regimenBody mass indexOxidative stressResearch ArticleOxidative Medicine and Cellular Longevity
researchProduct

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

2021

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic contr…

0301 basic medicineAgonistendocrine systemmedicine.drug_classDiseasePharmacologyCardiovascular SystemGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineGlucagon-Like Peptide 1Diabetes mellitusMedicineHumansHypoglycemic AgentsReceptorGlucagon-like peptide 1 receptorPharmacologyKidneybusiness.industrydigestive oral and skin physiologyType 2 Diabetes Mellitusmedicine.diseaseGlucagon-like peptide-1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Cardiovascular Diseasesbusinesshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryBritish journal of pharmacology
researchProduct

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats

2019

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are hormones secreted from the enteroendocrine cells after a meal. They exert their actions through activation of G protein-coupled receptors (R), the GIPR and GLP-2R, respectively. Both have been reported to influence metabolism. The purpose of the study was to investigate the role of the hormones in the regulation of lipid and bone homeostasis by subchronic treatment with novel GIPR and GLP-2R antagonists. Rats were injected once daily with vehicle, GIPR, or GLP-2R antagonists for 3 weeks. Body weight, food intake, body composition, plasma lipoprotein lipase (LPL), adipokines, triglycerides and the mark…

0301 basic medicineAgonistmedicine.medical_specialtyendocrine systemmedicine.drug_classEndocrinology Diabetes and MetabolismAdipokine030209 endocrinology & metabolismSettore BIO/09 - Fisiologialcsh:Diseases of the endocrine glands. Clinical endocrinologyBone resorption03 medical and health sciencesEndocrinology0302 clinical medicineInternal medicinemedicineglucagon-like peptide-2 (GLP-2)ReceptorOriginal Researchlcsh:RC648-665ChemistryLeptindigestive oral and skin physiologyAntagonistGIP receptorGIP receptor antagonistReceptor antagonistlipid homeostasis030104 developmental biologyEndocrinologyglucose-dependent insulinotropic polypeptide (GIP)hormones hormone substitutes and hormone antagonistsHormoneFrontiers in Endocrinology
researchProduct

Subclinical gut inflammation in ankylosing spondylitis

2015

Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic…

0301 basic medicineAnkylosing spondylitis; Gut inflammation; Innate lymphoid cells; Interleukin-17; Interleukin-23; Adaptive Immunity; Animals; Cytokines; Disease Models Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity Innate; Inflammation; Inflammatory Bowel Diseases; Intestines; Macrophages; Mice; Spondylitis Ankylosing; Rheumatology; Medicine (all)MacrophageAdaptive ImmunityInterleukin-23Inflammatory bowel diseaseGastroenterologyMiceInterleukin 23InnateMedicineSubclinical infectionMedicine (all)Interleukin-17digestive oral and skin physiologyInnate lymphoid cellIntestineIntestinesCytokinesmedicine.symptomHumanAnkylosingmedicine.medical_specialtyDisease ModelInflammationdigestive system03 medical and health sciencesRheumatologyInternal medicineInnate lymphoid cellAnimalsHumansSpondylitis AnkylosingCytokineSpondylitisGut inflammationSpondylitiInflammationAnkylosing spondylitisAnimalbusiness.industryMacrophagesInflammatory Bowel DiseaseImmunityInflammatory Bowel Diseasesmedicine.diseaseImmunity InnateDysbiosiGastrointestinal MicrobiomeAnkylosing spondylitiDisease Models Animal030104 developmental biologyDysbiosisbusinessDysbiosisCurrent Opinion in Rheumatology
researchProduct

Controlled Transdermal Release of Antioxidant Ferulate by a Porous Sc(III) MOF

2020

Summary The Sc(III) MOF-type MFM-300(Sc) is demonstrated in this study to be stable under physiological conditions (PBS), biocompatible (to human skin cells), and an efficient drug carrier for the long-term controlled release (through human skin) of antioxidant ferulate. MFM-300(Sc) also preserves the antioxidant pharmacological effects of ferulate while enhancing the bio-preservation of dermal skin fibroblasts, during the delivery process. These discoveries pave the way toward the extended use of Sc(III)-based MOFs as drug delivery systems (DDSs).

0301 basic medicineAntioxidantmedicine.medical_treatmentHuman skin02 engineering and technologyArticleInorganic Chemistry03 medical and health sciencesmedicine[CHIM]Chemical Scienceslcsh:ScienceComputingMilieux_MISCELLANEOUSTransdermalMultidisciplinaryintegumentary systemChemistry021001 nanoscience & nanotechnologyBiocompatible materialControlled releaseCombinatorial chemistry3. Good healthChemistry030104 developmental biologyDrug deliveryMedicinelcsh:Q0210 nano-technologyDrug carrierMaterials Structure
researchProduct

Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome

2020

TP53 missense mutations leading to the expression of mutant p53 oncoproteins are frequent driver events during tumorigenesis. p53 mutants promote tumor growth, metastasis and chemoresistance by affecting fundamental cellular pathways and functions. Here, we demonstrate that p53 mutants modify structure and function of the Golgi apparatus, culminating in the increased release of a pro-malignant secretome by tumor cells and primary fibroblasts from patients with Li-Fraumeni cancer predisposition syndrome. Mechanistically, interacting with the hypoxia responsive factor HIF1α, mutant p53 induces the expression of miR-30d, which in turn causes tubulo-vesiculation of the Golgi apparatus, leading …

0301 basic medicineBiopsyGeneral Physics and AstronomyGolgi ApparatusAnimals Biopsy Breast Neoplasms Cell Line Tumor Cell Transformation Neoplastic Female Fibroblasts Gene Expression Regulation Neoplastic Golgi Apparatus Humans Hypoxia-Inducible Factor 1 alpha Subunit Li-Fraumeni Syndrome Mice MicroRNAs Microtubules Mutation Primary Cell Culture Secretory Vesicles Signal TransductionSkin Tumor Microenvironment Tumor Suppressor Protein p53 Xenograft Model Antitumor Assays02 engineering and technologymedicine.disease_causeCell TransformationMicrotubulesSettore BIO/09 - FisiologiaMetastasisLi-Fraumeni SyndromeMiceTumor MicroenvironmentGolgisecretory machinerySuper-resolution microscopyAnimals; Biopsy; Breast Neoplasms; Cell Line Tumor; Cell Transformation Neoplastic; Female; Fibroblasts; Gene Expression Regulation Neoplastic; Golgi Apparatus; Humans; Hypoxia-Inducible Factor 1 alpha Subunit; Li-Fraumeni Syndrome; Mice; MicroRNAs; Microtubules; Mutation; Primary Cell Culture; Secretory Vesicles; Signal Transduction; Skin; Tumor Microenvironment; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assayslcsh:ScienceSkinMultidisciplinaryTumorChemistrymutant p53QCell migrationMicroRNASecretomics021001 nanoscience & nanotechnologyCell biologyGene Expression Regulation NeoplasticCell Transformation NeoplasticsymbolsFibroblastmiR-30dFemaleHypoxia-Inducible Factor 10210 nano-technologyBreast NeoplasmHumanSignal TransductionCancer microenvironmentStromal cellSecretory VesicleSciencePrimary Cell CultureBreast NeoplasmsMicrotubuleGolgi ApparatuSettore MED/08 - Anatomia Patologicaalpha SubunitGeneral Biochemistry Genetics and Molecular BiologyArticleCell Line03 medical and health sciencessymbols.namesakeCell Line TumormedicineAnimalsHumansSettore MED/05 - Patologia ClinicaSecretionTumor microenvironmentNeoplasticAnimalSecretory VesiclesGeneral ChemistryOncogenesGolgi apparatusHDAC6FibroblastsMicroreviewHypoxia-Inducible Factor 1 alpha SubunitmicroenvironmentXenograft Model Antitumor AssaysMicroRNAs030104 developmental biologyGene Expression RegulationMutationlcsh:QTumor Suppressor Protein p53Carcinogenesis
researchProduct

LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness

2020

One aim of cancer therapies is to induce apoptosis of tumor cells. Efficient removal of the apoptotic cells requires coordinated efforts between the processes of efferocytosis and LC3-associated phagocytosis (LAP). However, this activity has also been shown to produce anti-inflammatory and immunosuppressive signals that can be utilized by live tumor cells to evade immune defense mechanisms, resulting in tumor progression and aggressiveness. In the absence of LAP, mice exhibit suppressed tumor growth during efferocytosis, while LAP-sufficient mice show enhanced tumor progression. Little is known about how LAP or its regulators directly affect efferocytosis, tumor growth and treatment respons…

0301 basic medicineCancer ResearchPhagocytosisReviewtumor cell apoptosislcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineCytotoxic T cellEfferocytosisefferocytosistumor immune responseTumor microenvironmentbusiness.industrydigestive oral and skin physiologyCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensM2 macrophage activation030104 developmental biologyOncologyApoptosisTumor progression030220 oncology & carcinogenesisCancer cellLAPCancer researchbusinesshuman activitiesFrontiers in Oncology
researchProduct